SCHEMBL3847028

SCHEMBL3847028

CCOC(=O)c1c(O)c(-c2ccc(OC)cc2)n[nH]c1=O

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.57
HTT P42858 2/20 0.57
MAPK10 P53779 1/20 0.57
POLB P06746 2/20 0.53
GAA P10253 2/20 0.53
MAPT P10636 7/20 0.53
NPC1 O15118 3/20 0.53
RAB9A P51151 3/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
KDM4E B2RXH2 1/20 0.52
GRM6 O15303 1/20 0.47
TP53 P04637 5/20 0.47
JAK2 O60674 1/20 0.47
JAK3 P52333 1/20 0.47
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
NPSR1 Q6W5P4 1/20 0.46
AURKA O14965 1/20 0.45
MAPK1 P28482 1/20 0.45
TDP1 Q9NUW8 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6256682 0.88 POLB (0.60) SMN1; SMN2HTTMAPK10POLBGAA
SCHEMBL3847941 0.86 KDM4E (0.53) POLBGAAMAPTNPC1RAB9A
SCHEMBL3846746 0.86 KDM4E (0.53) POLBMAPTNPC1RAB9AKDM4E
SCHEMBL3851864 0.86 KDM4E (0.53) SMN1; SMN2HTTMAPK10GAAMAPT
SCHEMBL3847496 0.86 HPGDS (0.60) SMN1; SMN2POLBGAAMAPTNPC1
SCHEMBL3849587 0.84 KDM4E (0.51) SMN1; SMN2HTTMAPK10POLBGAA
SCHEMBL12398411 0.80 SMN1; SMN2 (0.66) SMN1; SMN2HTTMAPK10POLBGAA
SCHEMBL7463609 0.80 SMN1; SMN2 (0.62) SMN1; SMN2HTTMAPK10POLBGAA
SCHEMBL3851307 0.79 KDM4E (0.44) POLBKDM4EHPGDSPDE4D
SCHEMBL3855924 0.79 ALOX5 (0.48) SMN1; SMN2HTTPOLBMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2889289-A1 Pyridazine-dione N-substituted glycine derivatives as HIF hydroxylase inhibitors GlaxoSmithKline LLC (US) 2015-07-01 EP disclosed
US-RE44613-E1 N-substituted glycine derivatives: hydroxylase inhibitors GLAXOSMITHKLINE LLC (US) 2013-11-26 US disclosed
US-7608621-B2 Such as n-{[2-[(4-bromo-2-fluorophenyl)methyl]-5-hydroxy-6-(1-methylethyl)-3-oxo-2,3-dihydro-4-pyridazinyl]carbonyl}glycine; anemia; increasing erythropoietin production SMITHKLINE BEECHAM, CORP. (US) 2009-10-27 US disclosed
US-20080214549-A1 N-Substituted Glycine Derivatives: Hydroxylase Inhibitors GLAXOSMITHKLINE LLC 2008-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214549-A1 N-Substituted Glycine Derivatives: Hydroxylase Inhibitors EGLN2, EGLN3, HIF1AN SMN1; SMN2 3490/4885HTT 2198/4885MAPK10 3657/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.